Swiss National Bank Has $59.97 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Swiss National Bank reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 448,800 shares of the life sciences company's stock after selling 24,100 shares during the period. Swiss National Bank owned 0.28% of Illumina worth $59,973,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Golden State Wealth Management LLC bought a new stake in Illumina in the 4th quarter valued at $32,000. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the 4th quarter worth about $45,000. Assetmark Inc. increased its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after purchasing an additional 141 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $0.20 on Wednesday, hitting $84.96. The company had a trading volume of 2,609,915 shares, compared to its average volume of 2,090,646. The stock has a 50 day moving average price of $111.38 and a 200 day moving average price of $129.20. The stock has a market cap of $13.46 billion, a price-to-earnings ratio of -11.06, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Morgan Stanley lowered their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. Stephens reissued an "overweight" rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. Citigroup reduced their price objective on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Robert W. Baird cut their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. Finally, Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.